SCHEMBL14200520

SCHEMBL14200520

CCOCCOCc1cccc(C(C)C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 1/20 0.43
BACE1 P56817 1/20 0.43
KDM4E B2RXH2 2/20 0.41
TSHR P16473 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.38
RXRA P19793 2/20 0.37
GRIN1 Q05586 2/20 0.37
GRIN2B Q13224 2/20 0.37
HDAC4 P56524 2/20 0.37
HDAC8 Q9BY41 2/20 0.37
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
TACR1 P25103 4/20 0.35
HTT P42858 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MDM4 O15151 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10154614 0.91 KDM4E (0.41) CTSDBACE1KDM4ETSHRMRGPRX4
SCHEMBL5987241 0.88 CTSD (0.51) CTSDBACE1KDM4ETSHRMRGPRX4
SCHEMBL14001984 0.87 CTSD (0.40) CTSDBACE1KDM4ETSHRMRGPRX4
SCHEMBL22849031 0.82 KDM4E (0.40) KDM4ETSHRHDAC4HDAC8ALDH1A1
SCHEMBL10121249 0.79 TACR1 (0.43) CTSDBACE1MRGPRX4HDAC4HDAC8
SCHEMBL26723842 0.78 MRGPRX4 (0.43) CTSDBACE1KDM4EMRGPRX4RXRA
SCHEMBL26726801 0.78 MRGPRX4 (0.46) CTSDBACE1KDM4EMRGPRX4RXRA
SCHEMBL10178623 0.78 HDAC4 (0.46) TSHRMRGPRX4HDAC4HDAC8ALDH1A1
SCHEMBL16919633 0.78 HDAC4 (0.41) CTSDBACE1KDM4ETSHRMRGPRX4
SCHEMBL14228549 0.77 IDO1 (0.56) ALDH1A1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778874-B2 Glycopeptide antibiotic monomer derivatives NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2014-07-15 US disclosed
US-20080097078-A1 Antibacterial activity against vancomycin-resistant bacteria SHIONOGI & CO., LTD. (JP) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080097078-A1 Antibacterial activity against vancomycin-resistant bacteria CSGALNACT1, MON2, NR2C2 CTSD 4528/4885BACE1 1431/4885KDM4E 4340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.